Clear Harbor Asset Management LLC Has $61,000 Holdings in Context Therapeutics Inc. (NASDAQ:CNTX)

Clear Harbor Asset Management LLC lifted its stake in Context Therapeutics Inc. (NASDAQ:CNTX) by 60.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,804 shares of the company’s stock after acquiring an additional 21,804 shares during the period. Clear Harbor Asset Management LLC owned approximately 0.08% of Context Therapeutics worth $61,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of CNTX. State Street Corp grew its position in Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after purchasing an additional 19,800 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Context Therapeutics by 63.4% in the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after buying an additional 25,300 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Context Therapeutics during the third quarter worth about $89,000. Affinity Asset Advisors LLC increased its stake in Context Therapeutics by 392.4% during the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after acquiring an additional 1,290,323 shares during the period. Finally, Franklin Resources Inc. acquired a new position in Context Therapeutics in the 3rd quarter valued at approximately $3,689,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Wall Street Analysts Forecast Growth

CNTX has been the topic of a number of research reports. JMP Securities initiated coverage on Context Therapeutics in a research report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective on the stock. Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. Finally, D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research report on Wednesday, January 15th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $6.33.

Context Therapeutics Price Performance

Shares of CNTX opened at $0.94 on Thursday. The company has a market capitalization of $70.34 million, a P/E ratio of -1.03 and a beta of 2.10. Context Therapeutics Inc. has a one year low of $0.89 and a one year high of $2.75. The business’s 50 day simple moving average is $1.32 and its 200-day simple moving average is $1.88.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.11). On average, sell-side analysts anticipate that Context Therapeutics Inc. will post -0.51 EPS for the current fiscal year.

Context Therapeutics Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.